Download PDF
Thromb Haemost 1977; 38(03): 0696-0700
DOI: 10.1055/s-0038-1651885
Original Article
Schattauer GmbH

Heparin Neutralizing Activity (HNA) and Antithrombin III in Coronary Artery Disease

G Cella   *
1   Istituto di Semeiotica Medica, Cattedra di Fisiopat. Cardiocircolat., University of Padua Medical School, Padua, Italy
,
R Russo
1   Istituto di Semeiotica Medica, Cattedra di Fisiopat. Cardiocircolat., University of Padua Medical School, Padua, Italy
› Author Affiliations
Further Information

Publication History

Received 31 January 1977

Accepted 02 June 1977

Publication Date:
04 July 2018 (online)

    Permissions and Reprints

Summary

Plasma from 14 patients with severe and diffuse coronary atherosclerosis has been compared with that obtained from a normal control group. While a decreased he parin-thrombin clotting time was demonstrated in the patient group, suggesting an increased level of circulating platelet factor 4, there was no significant alteration in plasma antithrombin III level. These results do not support a recent suggestion of a mild chronic intravascular coagulation in atherosclerosis.

* Present Address Thrombosis Unit Research, King’s College Hospital Medical School, Denmark Hill, London, Great Britain


 

  • References

  • 1 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 283.
    CrossrefPubMedGoogle Scholar
  • 2 Brunetti A, Shivazappa L, Cafiero F, Zucchetto M, Miraglia G, Stritoni P, Girolami A. 1974; Alcuni parametri coagulativi nei coronaropatici. Tentativo di definizione di uno stato ipecoagulabile. Bollettino della Società Italiana di Cardiologia 20: 517.
    PubMedGoogle Scholar
  • 3 Conley L. G, Hartmann R. C, Lalley J. S. 1948; The relationship of heparin activity to platelet concentration. Proceedings of the Society for Experimental Biology and Medicine 69: 284.
    PubMedGoogle Scholar
  • 4 Genton E, Weily H. S, Steele P. P. 1973; Platelets, thrombosis and coronary artery disease. Advances in Cardiology 9: 29.
    PubMedGoogle Scholar
  • 5 Hardisty R. M, Ingram G. I. C. 1965. Bleeding Disorders. Blackwell Scientific Publications; Oxford.:
    Google Scholar
  • 6 Hender U, Nilsson I. M. 1973; Antithrombin III in a clinical material. Thrombosis Research 3: 631.
    CrossrefPubMedGoogle Scholar
  • 7 Holger Madsen T. 1960; Heparin resistance in acute coronary occlusion, measured by the plasma heparin thrombin time. Acta Haematologica 23: 195.
    CrossrefPubMedGoogle Scholar
  • 8 Käser-Glanzmann R, Jakobova M, Lüscher E. F. 1972; Isolation and some properties of the heparin-neutralising factor (PF4) released from human blood platelets. Experientia 28: 1221.
    CrossrefPubMedGoogle Scholar
  • 9 Marciniak E, Florey C. H, De Simone P. A. 1974; Familial thrombosis due to antithrombin III deficiency. Blood 43: 219.
    PubMedGoogle Scholar
  • 10 Nath N, Lowery G. T, Niewiarowski S. 1975; Antigenic and antiheparin properties of human platelet factor 4 (PF4). Blood 45: 537.
    PubMedGoogle Scholar
  • 11 O’Brien J. R, Etherington M, Jamieson S, Klaber M. R, Lincoln S. V. 1974; Platelet function long after arterial and venous thrombosis. Thrombosis et Diathesis Haemorrhagica 31: 279.
    PubMedGoogle Scholar
  • 12 O’Brien J. R. 1974; Anti-thrombin III and heparin clotting times in thrombosis and atherosclerosis. Thrombosis et Diathesis Haemorrhagica 32: 116.
    PubMedGoogle Scholar
  • 13 O’Brien J. R, Etherington M, Jamieson S, Lawford P, Sussex J, Lincoln S. V. 1975; Heparin neutralizing activity test in the diagnosis of acute myocardial infarction. Journal of Clinical Pathology 28: 975.
    CrossrefPubMedGoogle Scholar
  • 14 Sagar S, Stamatakis J. D, Thomas D. P, Kakkar V. V. 1976; Oral contraceptives, antithrombin III activity and postoperative deep vein thrombosis. Lancet 1: 509.
    PubMedGoogle Scholar
  • 15 Sagar S, Stamatakis J. D, Higgins A. F, Nairn D, Maffei F. H, Thomas D. P, Kakkar V. V. 1976; Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total hip replacement. Lancet 1: 1151.
    PubMedGoogle Scholar
  • 16 Yin E. T, Wessler S, Stoll P. J. 1971; Biological properties of the naturally occurring plasma inhibitor to activated Factor X. Journal of Biological Chemistry 246: 3703.
    PubMedGoogle Scholar
  • 17 Yin E. T, Wessler S, Butler J. V. 1973; Plasma heparin: A unique, practical submicrogram sensitive assay. Journal of Laboratory and Clinical Medicine 81: 289.
    PubMedGoogle Scholar